CAS No.: Undisclosed
Molecular Formula: Undisclosed | Molecular Weight: Undisclosed
Dosage Form: Oral Tablet | Manufacturer: Undisclosed (In R&D Stage)
Product Overview
Osmapimod is an oral small-molecule inhibitor, mainly targeting inflammation-related pathways, with potential therapeutic effects on inflammatory diseases and autoimmune diseases, currently in clinical research stage globally.
Mechanism of Action
• Specifically regulates key inflammatory pathways, inhibits the release of pro-inflammatory factors (such as TNF-α, IL-17), and alleviates abnormal inflammatory responses in the body.
Molecular Formula: Undisclosed | Molecular Weight: Undisclosed
Dosage Form: Oral Tablet | Manufacturer: AstraZeneca (Acquired from Dezima Pharmaceuticals)
Product Overview
TA-8995 is an oral small-molecule CETP (Cholesteryl Ester Transfer Protein) inhibitor, initially developed by Dezima Pharmaceuticals and later acquired by AstraZeneca, with remarkable lipid-lowering efficacy and promising clinical potential, previously in Phase Ⅱ clinical trials globally.
China [CN] 
Click enlarge Image